Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1

Conditions

Wilms Tumor 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Bone Neoplasms 1Blast Crisis 1

Interventions

pembrolizumab 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Cyclophosphamide 5Radiosurgery 3Oncolytic Virotherapy 3Nivolumab 3Injections 3Gemcitabine 3Drug Therapy 3Biopsy 3fludarabine 2belinostat 2Riluzole 2Paclitaxel 2Ipilimumab 2Filgrastim 2Docetaxel 2Cisplatin 2Celecoxib 2Carboplatin 2Bortezomib 2Blood Specimen Collection 2Amifostine 2AH 111585 2tislelizumab 1spartalizumab 1seribantumab 1selpercatinib 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Etanercept × Sarcoma × Clear all
NCT00127387 2012-06-26

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

The University of Texas Health Science Center at San Antonio

Phase 2/3 Terminated
54 enrolled
GenitourinarySarcomaThoracic

Bone Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡